Codexis acquires BioCatalytics
US biotech company Codexis has acquired enzymer producer BioCatalytics, of Pasadena, California to create a global leader in biocatalyst design, synthesis and use.
US biotech company Codexis has acquired enzymer producer BioCatalytics, of Pasadena, California to create a global leader in biocatalyst design, synthesis and use.
The acquisition combines two companies focused on biocatalysis to develop new manufacturing processes that are shorter, faster and cleaner than those using conventional chemical synthesis technology.
"This acquisition creates a market leader in biocatalysis, bringing the power of clean bio-based manufacturing technology to customers seeking alternatives to undesirable or unsustainable chemical processes," said Dr Alan Shaw, president and ceo of Codexis.
"Our expanded company will provide a broad product and service platform to serve the pharmaceutical industry worldwide, and will also offer exciting new enzyme technologies to our bioindustrial partners."
Dr David Rozzell, president of BioCatalytics, is joining Codexis as vice president, enzyme products and services in the pharma services group, reporting to Dr Peter Seufer-Wasserthal, vice president and general manager, pharma services group.
"We are combining the extensive enzyme product lines of BioCatalytics with Codexis' powerful technology for enzyme customisation and improvement. This combination will allow us to bring green chemistry alternatives to an unparalleled range of chemical reactions and offer our customers the broadest range of enzyme products and services in the world," he said. BioCatalytics employees will remain at the current location in Pasadena.
